SGLT2 Inhibitors and Their Impact on Cardio-Renal Benefits

Uncover the significant cardio-renal benefits that SGLT2 inhibitors provide for those managing cardiovascular and kidney concerns.

Abstract

In this educational post, I will guide you through the latest evidence-based findings on Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors and their profound impact on the management of type 2 diabetes, chronic kidney disease (CKD), and heart failure. My goal is to share a personal journey that led me to a lifelong focus on diabetes care and cardiorenal health, and to present the latest evidence on how these medications provide robust cardiorenal protection beyond glucose control. Drawing from my clinical experience, the work of leading researchers, and a real-world patient case, we will explore the mechanisms of these medications, their approved indications, and the nuances of patient selection. We’ll examine major clinical trials that highlight the significant cardiovascular and renal benefits of SGLT2 inhibitors, often independent of their glucose-lowering effects.

This post will also detail our integrated approach at Injury Medical Clinic PA in El Paso, Texas, where I, as a Doctor of Chiropractic and Family Nurse Practitioner, collaborate with our Medical Director, Dr. Maria Guadalupe Cardenas, an internist with over 40 years of experience. We will discuss how we integrate medical direction, integrative chiropractic care, functional medicine, and rehabilitation strategies to create a comprehensive, multidisciplinary treatment plan for our patients with complex chronic conditions such as diabetes, heart failure, CKD, and personal injury. We combine medical precision, chiropractic biomechanical correction, metabolic support, and patient-centered education using modern research methods and evidence-based protocols to optimize whole-person health.

My Path to Diabetes and Cardiorenal Care

I’m Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. My interest in diabetes began in my early life, shaped by family experiences that revealed the immense impact of lifestyle on health outcomes. Caring for a loved one taught me how routine choices—food, movement, medication adherence, and blood sugar monitoring—can change the trajectory of disease. That formative experience drove my commitment to education, prevention, and practical, integrative solutions that make sense for patients and providers alike.

From the beginning of my clinical work, I have emphasized the synergy between modern medical science and integrative chiropractic care—addressing metabolic dysfunctions while restoring physical function. Over the years, my practice has grown into a multidisciplinary ecosystem where cardiometabolic medicine, functional nutrition, chiropractic biomechanics, and rehabilitation meet.

• Key takeaways from my clinical journey:

• • The most meaningful outcomes come from aligning medical therapy with lifestyle change and movement.
  • Patients need clear, practical explanations of mechanisms: why this medication, why this exercise, why this nutrition plan.
  • Prevention and early intervention reduce complications and improve quality of life.

Our Integrative Team: Medical Direction and Chiropractic Care in One Clinic

At Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, my philosophy is rooted in a multidisciplinary and integrative approach to patient care. I work closely with Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is a board-certified internist (NPI #1164426749, Texas MD License #J2933) with more than four decades of experience, serving as our Medical Director and Collaborative Physician. Her role is crucial in providing medical oversight and direction, ensuring our diagnostic and treatment protocols meet the highest standards of medical care. This multidisciplinary setup, in which an MD provides medical direction alongside a chiropractor, is fundamental to our practice and is common in integrative or injury care clinics. It allows us to seamlessly integrate integrative chiropractic care with internal medicine, functional medicine, personal injury care, and rehabilitation.

• What this looks like in practice:

• Cardenas oversees diagnostics, comorbidity management (diabetes, hypertension, CKD, heart failure), medication decisions, and coordinates with pharmacy and insurers.
• I deliver evidence-based chiropractic care, spinal and joint adjustments, neuromuscular rehabilitation, and functional medicine protocols, including diabetes self-management education (DSME).
• We coordinate care plans for personal injury, metabolic optimization, and cardiometabolic risk reduction.
• We use shared care pathways, continuous patient education, and digital follow-up to sustain outcomes.

Together, we ensure treatments are medically safe, biomechanically sound, metabolically effective, and aligned with the latest research. This synergy ensures a holistic and robust care plan tailored to each individual’s needs.

The Interconnected Crisis: Diabetes, Heart Failure, and Kidney Disease

Before diving into the specifics of SGLT2 inhibitors, it’s essential to understand the sheer scale of the conditions they are designed to treat. Based on global data spanning from 1990 to 2017, the numbers are sobering. We can only assume that these figures are even higher today, in 2026.

• Chronic Kidney Disease (CKD): Globally, there were an estimated 5 million cases, with a 29% increase in prevalence noted during that period. In the United States alone, the annual cost impact was $48 billion.
• Heart Failure: The global prevalence stood at 64 million cases, a 36% increase, with a staggering global cost of $346 billion per year.

To truly grasp the human cost, researchers use a metric called the Disability-Adjusted Life Year (DALY). One DALY represents the loss of one year of full, healthy life due to premature death or disability. The numbers are heartbreaking:

• CKD was responsible for 35.8 million DALYs—that’s millions of years of healthy life lost.
• Heart failure-related conditions accounted for even more:

• • Ischemic Heart Disease: 182 million DALYs
  • Hypertensive Heart Disease: 5 million DALYs
  • Cardiomyopathy and Myocarditis: 14 million DALYs

This isn’t just a matter of statistics; it’s a profound loss of life and quality of life on a global scale.

The Ties That Bind: A Vicious Cardiorenal Cycle

I often refer to the relationship between type 2 diabetes, CKD, and heart failure as “The Ties That Bind.” These three conditions are deeply intertwined, creating a vicious cycle in which each exacerbates the others. During my training as a Nurse Practitioner, I logged countless patient cases. Whenever I entered the diagnosis code for type 2 diabetes, it was almost invariably followed by codes for hypertension, hyperlipidemia, CKD, or heart failure. This was living proof of the theoretical knowledge I had about how diabetes fuels inflammation and cardiovascular complications.

In the United States, an estimated 38.4 million adults have type 2 diabetes, and 20% to 40% of them also have CKD. This means 7 to 15 million people are on a path of declining kidney function, making progression to heart failure or other cardiovascular events almost inevitable. This is why we speak of cardiorenal complications of diabetes.

The Pathophysiology of Cardiorenal Damage Explained

Understanding how this damage occurs is the foundation for effective treatment. When I explain this to my patients, I use a simple analogy.

1. The “Sticky Blood” Analogy: Diabetes causes high blood sugar. I ask them to think of a very sweet liquid, like honey or syrup. It’s thick, gooey, and sticky. Now, imagine that thick, oozing fluid is your blood. How would your heart pump it? The immediate response is always, “The heart would have to pump extra hard.” This is exactly right. Hyperglycemia (high blood sugar) alone dramatically increases the heart’s workload.
2. The “Inflammatory Sugar” Analogy: I then ask them to imagine holding a hard candy in their mouth, against the inside of their cheek, for an hour. How would that spot feel afterward? They describe it as raw, irritated, or hardened. Sugar is incredibly inflammatory. Now, if the sugar in your blood is high, where does that blood go? Everywhere. It hardens the walls of your blood vessels and scrapes the delicate filters of your kidneys.

This simple explanation helps patients visualize the complex processes. Physiologically, high blood sugar sets off a disastrous cascade:

• Volume Expansion & Hyperfiltration: High blood glucose pulls water from cells into the bloodstream (osmotic diuresis). This increases blood volume and drives renal hyperfiltration, causing intraglomerular hypertension that damages podocytes and accelerates CKD.
• RAAS Activation: Increased blood volume and pressure paradoxically lead to decreased perfusion to vital organs. The kidneys sense this and activate the Renin-Angiotensin-Aldosterone System (RAAS). Chronic RAAS activation causes structural damage and fibrosis in the heart muscle.
• Impaired Glucose Threshold: In a healthy person, the kidneys excrete excess glucose in the urine. In patients with diabetes, this threshold is “numbed.” The kidneys pathologically reabsorb glucose even when blood sugar is dangerously high, worsening the hyperglycemia.

This destructive feedback loop is why we need therapies that can intervene at multiple points.

Why SGLT2 Inhibitors Matter: Beyond Glucose Control

This brings us to the star of our discussion: Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors. These medications—such as empagliflozin, dapagliflozin, and canagliflozin—represent a paradigm shift in how we manage these interconnected diseases.

• Core mechanisms of action:

• Renal glucose-sodium transport blockade: SGLT2 inhibition reduces glucose and sodium reabsorption in the proximal tubule, directly lowering blood sugar by increasing urinary glucose excretion.
• Tubuloglomerular feedback improvement: Increased sodium delivery to the macula densa resets afferent arteriolar tone, reducing intraglomerular hypertension—a key driver of CKD progression.
• Hemodynamic effects: Mild diuresis and natriuresis lower preload and afterload, benefiting heart failure physiology.
• Metabolic shifts: Favoring energy efficiency, possibly by increasing ketone availability to myocardial tissue, which improves myocardial energetics.
• Weight and blood pressure reductions: Modest improvements support overall cardiometabolic health.

These findings demonstrate that SGLT2 inhibitors are not simply glucose-lowering drugs—they are cardiorenal modifiers that change disease trajectories.

Approved Indications and Clinical Guidelines

The benefits of SGLT2 inhibitors are so significant that they are now recommended for reasons that go far beyond just lowering A1C.

FDA-Approved Indications:

• Improving glycemic control in adults with type 2 diabetes.
• Reducing the risk of major adverse cardiovascular events (MACE).
• Reducing the risk of heart failure hospitalization.
• Reducing the risk of eGFR decline and end-stage kidney disease.
• Improving outcomes in patients with heart failure, even in those without diabetes.

Both the American Diabetes Association (ADA) and the American Association of Clinical Endocrinology (AACE) have issued strong recommendations. Their guidelines state that for patients with type 2 diabetes who have established or high-risk cardiovascular disease, heart failure, or CKD, an SGLT2 inhibitor (or a GLP-1 RA) should be part of their treatment plan, irrespective of their A1C level. This marks a monumental shift from a glucose-centric to an organ-protection approach.

---

Cardiometabolic Risk *Causes & Effects*- Video

---

Key Clinical Trials: The Evidence Speaks for Itself

The widespread adoption of SGLT2 inhibitors is supported by robust, large-scale clinical trials demonstrating their powerful cardiorenal benefits.

Cardiovascular Benefit Trials

• EMPA-REG OUTCOME: This trial with empagliflozin (Jardiance) showed a 14% reduction in MACE and a remarkable 35% reduction in hospitalizations for heart failure.
• CREDENCE: Using canagliflozin (Invokana), this trial demonstrated a 20% reduction in MACE and a 39% reduction in hospitalization for heart failure.
• VERTIS-CV: Using ertugliflozin, this trial showed more modest but still present benefits.

Renal Benefit Trials

• CREDENCE: This landmark trial was stopped early due to overwhelming efficacy. Canagliflozin showed a 30% relative risk reduction in the primary composite outcome of end-stage kidney disease (ESRD), doubling of creatinine, or renal/CV death.
• DAPA-CKD: Using dapagliflozin (Farxiga), this trial included patients with and without diabetes. It showed a 39% reduction in the relative risk of the primary renal outcome.
• EMPA-KIDNEY: In this trial using empagliflozin, there was a 28% relative risk reduction in the risk of progression of kidney disease or cardiovascular death.

These trials consistently show that SGLT2 inhibitors protect the heart and kidneys, slowing disease progression and saving lives.

Clinical Case: A Stepwise Pathway to Stability

To illustrate our integrative approach, I’ll walk you through the real-world case of a patient, “R.B.”, a 73-year-old Hispanic male. His profile is a classic example of “The Ties That Bind.”

History: Type 2 diabetes for 12 years, CKD stage 3 (eGFR 43), hypertension, and hyperlipidemia.

Medications: Metformin, Glipizide (a sulfonylurea), and a high dose of basal insulin.

Key findings:

• A1C 10.2%
• eGFR 43, previously 55
• Daytime blood sugars: 200–300 mg/dL
• Night: symptomatic lows (shakiness, sweating), treated with juice or sweets.
• Refused continuous glucose monitoring (CGM) initially due to fear of a “big needle.”

This pattern—daytime hyperglycemia with nocturnal hypoglycemia—is classic. The high basal insulin dose caused overnight lows, triggering a counterregulatory hormone surge (epinephrine, cortisol) that, combined with reactive eating, drove his daytime blood sugar levels sky-high.

Treatment Plan: From Safety to Cardio-Renal Protection

Our first task was to break this cycle. Under the medical direction of Dr. Cardenas, our plan unfolded in stages.

Part One: Safety, De-escalation, and Education

I started with comprehensive DSME to explain the mechanics. We made immediate changes:

1. Stop glipizide to reduce unpredictable, meal-independent insulin release.
2. Decrease basal insulin to limit nocturnal lows.
3. Teach carbohydrate portions and strategic substitutions (less rice, more protein).

Part Two: Overcoming CGM Barriers

The patient’s needle fear was a major barrier. I demonstrated a CGM device, showing him the tiny, flexible filament that stays under the skin rather than a large needle. This on-the-spot education worked; he agreed to try it. CGM is transformative, as it provides real-time biofeedback that accelerates behavioral change.

Part Three: Adding SGLT2i with Renal and Cardiac Intent

After two weeks, his daytime glucose improved, and nocturnal lows stopped. I ordered a C-peptide test to confirm his body was still making its own insulin. I explain it to patients this way: the C-peptide is the candy wrapper, the insulin is the candy. Measuring the wrapper tells us if the factory is still working. His was normal, which reduces the risk of DKA with SGLT2 inhibitors.

With this confirmation, we initiated dapagliflozin 5 mg daily and further reduced his insulin.

Part Four: Optimization with a GLP-1 RA

At his three-month follow-up, his A1C dropped from 10.2% to 8.2%, and his eGFR rose from 43 to 53. We then switched him from a DPP-4 inhibitor to semaglutide (a GLP-1 RA). GLP-1 RAs enhance glucose-dependent insulin secretion, slow gastric emptying, and reduce appetite, further supporting weight loss and lowering cardiovascular risk.

Seven-Month Milestone: Stabilization

At seven months, his average blood sugar was ~150 mg/dL, his A1C was 7.2%, and his eGFR was stable at 55. He had no nocturnal lows and no postprandial spikes, all achieved without adding mealtime insulin. This comprehensive approach, combining medication de-escalation with modern, organ-protective therapies, stabilized his health.

Safety, Side Effects, and Patient Selection

While transformative, SGLT2 inhibitors require careful patient selection and education.

• Common side effects:

• • Genital mycotic infections due to glycosuria; hygiene education is key.
  • Volume depletion or dizziness; assess diuretic use and encourage hydration.

• Contraindications & Special Considerations:

• • Diabetic Ketoacidosis (DKA): Contraindicated in Type 1 diabetes and in patients with a history of DKA. Euglycemic DKA is a rare but serious risk.
  • Sick Days: We pause SGLT2i during acute illness, major surgery, or when there is a risk of severe dehydration.
  • Ketogenic Diet: Combining a keto diet with an SGLT2 inhibitor is dangerous and significantly increases DKA risk.
  • Foot Infections: Though an earlier amputation warning was removed for most agents, I remain cautious. In my clinical observation, I have noticed delayed healing of foot infections. I often collaborate with podiatrists and may temporarily switch therapies until a serious infection resolves.

Integrating Chiropractic Care with Cardiorenal Medicine

Integrative chiropractic care complements medical therapy by optimizing biomechanics, autonomic balance, and functional capacity—core elements for patients with cardiometabolic disease.

• How chiropractic fits:

• • Spinal and joint adjustments can reduce nociceptive input and sympathetic overactivity, supporting blood pressure regulation and stress resilience.
  • Neuromuscular rehabilitation improves gait, mechanics, and endurance—critical where deconditioning and neuropathy are common.
  • Pain reduction enables activity, which supports glucose uptake by working muscles.
  • Postural correction and breathing mechanics improve diaphragmatic excursion and oxygenation—beneficial for heart failure- and CKD-related fatigue.

• Functional medicine synergy:

• • We assess mitochondrial function, inflammation, and gut health.
  • Protocols include anti-inflammatory nutrition, targeted supplementation, and circadian alignment to improve insulin signaling and autonomic tone.

• Clinical observations from my practice:

• • Patients who combine chiropractic adjustments, graded exercise, and SGLT2 inhibitors often report improved energy, reduced edema, and greater activity tolerance.
  • Structured movement plans lower HbA1c and improve resting heart rate variability, a marker of autonomic health. Our outcomes are strengthened by consistent follow-up and digital education tools available through our platforms, including resources at dralexjimenez.com and professional updates on my LinkedIn profile.

By improving physical function and stress physiology, chiropractic care reduces adrenergic drivers of hyperglycemia and complements the effects of medication.

Bringing It All Together in El Paso

Our clinic in El Paso, Texas, offers a unique environment where internal medicine leadership and chiropractic innovation unite. Under Dr. Cardenas’s vigilant medical direction and my integrative chiropractic and functional approach, patients receive cohesive, whole-person care focused on cardiorenal protection and lasting quality of life.

• What sets our model apart:

• • Medical safety and pharmacologic excellence from a seasoned internist.
  • Biomechanical optimization and rehabilitation from an experienced chiropractor and functional medicine practitioner.
  • Personalized education, digital support, and continuous outcome tracking.

We invite patients and providers to experience an integrated path to health—grounded in science, guided by mechanism, and delivered with compassion.

References

• Battelino et al., 2019: Clinical targets for continuous glucose monitoring
• Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (McMurray et al., 2019). New England Journal of Medicine.
• Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (Packer et al., 2020). New England Journal of Medicine.
• Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (Perkovic et al., 2019). New England Journal of Medicine.
• Dapagliflozin in Patients with Chronic Kidney Disease (Heerspink et al., 2020). New England Journal of Medicine.
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (Zinman et al., 2015). New England Journal of Medicine.
• Empagliflozin in patients with chronic kidney disease (The EMPA-KIDNEY Collaborative Group, 2023). New England Journal of Medicine.
• Gerstein et al., 2019: Dulaglutide cardiovascular outcomes (REWIND)
• Marso et al., 2016: Semaglutide cardiovascular outcomes (SUSTAIN-6)
• Packer, 2020: SGLT2 mechanisms in heart failure
• Peters et al., 2015: DKA risk with SGLT2 inhibitors
• Zelniker & Braunwald, 2019: Cardiac and renal benefits of SGLT2/GLP-1 therapies

SEO Tags: SGLT2 inhibitors, cardiorenal benefits, diabetes care, heart failure, chronic kidney disease, integrative chiropractic, functional medicine, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, internal medicine oversight, El Paso clinic, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, empagliflozin, dapagliflozin, canagliflozin, cardiorenal syndrome, type 2 diabetes, kidney protection, cardiovascular benefits, evidence-based medicine, patient education, clinical practice, autonomic balance, rehabilitation, personal injury care, nocturnal hypoglycemia management, CGM education diabetes